TCRX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 2.76%

Insider Buying (Last 12 Months): $166,378.70

Insider Selling (Last 12 Months): $0.00

TScan Therapeutics Insider Trading History Chart

TScan Therapeutics Share Price & Price History

^$7.27

▲ +0.09 (1.25%)

As of 07/26/2024 01:00 AM ET

Days: 30 | 90 | 365

NEW AI developed by trader who won 1,129% (in 2 days)

From Monument Traders Alliance | Ad

Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands of Americans...

Click here to see how >>>

TScan Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/18/2023	Timothy J Barberich	Director	Buy	28,830	$4.89	$140,978.70	66,710
12/14/2023	Barbara Klencke	Director	Buy	5,000	$5.08	$25,400.00	30,000
6/2/2023	Timothy J Barberich	Director	Buy	37,880	$2.63	$99,624.40	37,880
5/31/2023	Lynx1 Capital Management Lp	Major Shareholder	Sell	25,400	$2.52	$64,008.00	5,224,600
12/27/2022	Brian M. Silver	CFO	Buy	2,842	$1.50	$4,263.00	29,727
5/18/2022	David P Southwell	CEO	Buy	25,000	$3.59	$89,750.00	171,569
3/24/2022	Brian M. Silver	CFO	Buy	15,000	$3.40	$51,000.00
9/23/2021	Zoran Zdraveski	Insider	Buy	4,716	$7.48	$35,275.68
9/21/2021	Brian M. Silver	CFO	Buy	5,000	$6.32	$31,600.00
9/20/2021	Gavin MacBeath	Insider	Buy	4,943	$6.22	$30,745.46

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

From Traders Agency | Ad

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

SEC Filings (Institutional Ownership Changes) for TScan Therapeutics (NASDAQ:TCRX)

82.83% of TScan Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

TScan Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
7/26/2024	Bank of New York Mellon Corp	116,658	$0.68M	0.0%	N/A	0.221%
5/10/2024	Vanguard Group Inc.	1,808,152	$14.36M	0.0%	+1.1%	3.776%
5/10/2024	Tocqueville Asset Management L.P.	212,200	$1.69M	0.0%	N/A	0.443%
4/17/2024	Cannon Global Investment Management LLC	17,500	$0.14M	0.4%	N/A	0.037%
2/14/2024	Pale Fire Capital SE	21,573	$0.13M	0.0%	+30.2%	0.045%
2/12/2024	Letko Brosseau & Associates Inc.	20,700	$0.12M	0.0%	-36.1%	0.043%
1/31/2024	abrdn plc	200,000	$1.17M	0.0%	N/A	0.418%
11/14/2023	Pale Fire Capital SE	16,575	$42K	0.0%	N/A	0.035%
11/9/2023	Letko Brosseau & Associates Inc.	32,400	$83K	0.0%	N/A	0.068%
8/15/2023	BVF Inc. IL	2,989,474	$7.47M	0.2%	N/A	12.338%
8/10/2023	Monashee Investment Management LLC	400,000	$1M	0.2%	N/A	1.651%
7/26/2023	Privium Fund Management B.V.	15,825	$40K	0.0%	N/A	0.065%
5/10/2023	Simplify Asset Management Inc.	546,916	$1.15M	0.2%	N/A	2.257%
2/15/2023	Tang Capital Management LLC	514,655	$0.80M	0.1%	-7.8%	2.137%
11/16/2022	Alphabet Inc.	1,077,080	$3.29M	0.2%	N/A	4.482%
11/15/2022	Tang Capital Management LLC	557,915	$1.70M	0.2%	-25.4%	2.322%
11/4/2022	Prudential Financial Inc.	11,000	$34K	0.0%	N/A	0.046%
11/1/2022	Privium Fund Management UK Ltd	15,825	$48K	0.1%	N/A	0.066%
5/17/2022	RA Capital Management L.P.	1,021,764	$2.86M	0.1%	-18.6%	4.299%
5/17/2022	Hhlr Advisors LTD.	669,513	$1.88M	0.0%	-47.8%	2.817%
4/26/2022	Marquette Asset Management LLC	28,895	$81K	0.0%	+33.7%	0.122%
2/15/2022	Deer Management Co. LLC	1,245,505	$5.61M	0.1%	N/A	5.240%
2/15/2022	Adage Capital Partners GP L.L.C.	550,000	$2.48M	0.0%	+10.8%	2.314%
1/19/2022	Marquette Asset Management LLC	21,618	$97K	0.0%	N/A	0.091%
11/16/2021	Schonfeld Strategic Advisors LLC	22,200	$0.19M	0.0%	N/A	0.093%
11/16/2021	Wellington Management Group LLP	139,566	$1.16M	0.0%	N/A	0.582%
11/15/2021	RA Capital Management L.P.	1,255,317	$10.47M	0.1%	N/A	5.238%
11/15/2021	Caas Capital Management LP	75,000	$0.63M	0.0%	N/A	0.313%
11/12/2021	DC Investments Management LLC	35,563	$0.30M	0.6%	N/A	0.148%
11/12/2021	DC Funds LP	630,000	$5.25M	20.6%	N/A	2.629%
11/9/2021	BlackRock Inc.	1,500,577	$12.52M	0.0%	N/A	6.261%
11/9/2021	Monashee Investment Management LLC	100,000	$0.83M	0.2%	N/A	0.417%

Data available starting January 2016

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $7.27

$6.95

$7.44

50 Day Range

MA: $7.43

$5.71

$9.51

52 Week Range

Now: $7.27

$1.93

$9.69

Volume

209,519 shs

Average Volume

259,023 shs

Market Capitalization

$384.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.82

Who are the company insiders with the largest holdings of TScan Therapeutics?: TScan Therapeutics' top insider shareholders include:
Lynx1 Capital Management Lp (Major Shareholder)
Timothy J Barberich (Director)
Barbara Klencke (Director)
Brian M Silver (CFO)
Learn More about top insider investors at TScan Therapeutics.
Who are the major institutional investors of TScan Therapeutics?: TScan Therapeutics' top institutional investors include:
Bank of New York Mellon Corp — 0.22%
Learn More about top institutional investors of TScan Therapeutics stock.
Which major investors are buying TScan Therapeutics stock?: Within the previous quarter, TCRX stock was acquired by institutional investors including:
Bank of New York Mellon Corp
In the previous year, these company insiders have bought TScan Therapeutics stock:
Lynx1 Capital Management Lp (Major Shareholder)
Timothy J Barberich (Director)
Barbara Klencke (Director)
Learn More investors buying TScan Therapeutics stock.